Public Health Archives - Page 4 of 35 - Boston Life Sciences Times

Capital Discipline Matters: Sam Zell’s Lessons for Every Entrepreneur

December 13, 2025

Kymera Therapeutics Closes Upsized $602 Million Public Offering, Underwriters Fully Exercise Option

December 12, 2025

Prilenia and Ferrer gain FDA approval to launch Phase 3 ALS study of pridopidine

December 11, 2025

THIS WEEK'S STORIES

Suffolk hires Roger Moore to strengthen healthcare construction leadership in California

December 11, 2025

Fondazione Telethon, Orphan Therapeutics Accelerator outline non-profit pathway for U.S. access to ultra-rare gene therapy

December 15, 2025

Cosette Pharmaceuticals Terminates Agreement to Acquire Mayne Pharma

December 12, 2025

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Public Health

Federal Health Leaders Join Food Allergy Fund Forum to Chart Future of Research and Innovation

Dexcom Reveals Global Diabetes Advocates for World Diabetes Day

Brighton Marine Launches $100,000 Basic-Needs Initiative to Support Boston Veterans

New Research: GLP-1 Therapies Could Reduce U.S. Mortality by 3.5% Over the Next Two Decades

ByHeart Expands Voluntary Nationwide Recall of Infant Formula as Investigation Continues

Most Read

Linus Health appoints Julie Wood, MD, MPH, FAAFP, as senior medical director for clinician engagement

Fondazione Telethon, Orphan Therapeutics Accelerator outline non-profit pathway for U.S. access to ultra-rare gene therapy

Sōlaria Biō study links gut barrier health, inflammation and bone density in breakthrough findings

DexCare Appoints Rakshay Jain as Chief Product Officer to Advance Patient Navigation Platform

EDITOR PICKS

Capital Discipline Matters: Sam Zell’s Lessons for Every Entrepreneur

Kymera Therapeutics Closes Upsized $602 Million Public Offering, Underwriters Fully Exercise Option

Prilenia and Ferrer gain FDA approval to launch Phase 3 ALS study of pridopidine

THIS WEEK'S STORIES

Suffolk hires Roger Moore to strengthen healthcare construction leadership in California

Fondazione Telethon, Orphan Therapeutics Accelerator outline non-profit pathway for U.S. access to ultra-rare gene therapy

Cosette Pharmaceuticals Terminates Agreement to Acquire Mayne Pharma

POPULAR CATEGORY

ABOUT US

FOLLOW US